# Tumor-Specificity Growth Factor Combined with Tumor Markers in Nuclear Medicine Imaging to Identify Prostate Cancer Osteonosus.

> **Reliability concern:** This paper was retracted on 2023-11-01. See notice: 10.1155/2023/9850875.

- **DOI:** [10.1155/2021/7380120](https://doi.org/10.1155/2021/7380120)
- **Rating:** Very Limited (1.7 out of 5)
- **Verdict:** A retrospective diagnostic accuracy study for prostate cancer bone disease whose circular reference standard and arithmetic errors invalidate its core performance claims.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-01
- **Evaluation page:** https://www.nabu.science/paper/10.1155%2F2021%2F7380120

## Strengths

- **Clinically relevant diagnostic question addressed** The study targets an important clinical problem — improving diagnostic accuracy for prostate cancer bone disease — combining imaging and biomarker approaches, which represents a meaningful diagnostic strategy framework.
  - Dimension: contribution
  - Location: §1 Introduction
- **Structured multi-method diagnostic comparison** The paper compares PET alone, TM alone, and combined TSGF+TM approaches with explicit diagnostic accuracy formulas, providing a framework for evaluating complementary diagnostic modalities.
  - Dimension: methodological rigour
  - Location: §2.5, §3.5–3.6, Figure 8
- **Real-world traction for combined diagnostics** The study addresses a genuine unmet need in oncology — clinicians managing advanced prostate cancer actively seek better tools for detecting bone metastasis — giving the research question inherent clinical relevance.
  - Dimension: application pathway
  - Location: §1 Introduction, §4 Conclusion

## Limitations

- **Circular reference standard invalidates diagnostic accuracy** Patients are classified into malignant and benign groups based on PET whole body bone imaging (§2.1), and PET is then evaluated as one of the index tests for diagnostic accuracy. This circularity means PET's performance metrics are self-referential and invalid.
  - Dimension: methodological rigour
  - Location: §2.1 Research Objects
- **Arithmetic inconsistency in core diagnostic metrics** The reported TM accuracy of 69.8% is mathematically impossible given the stated sensitivity (79.2%), specificity (94.6%), and sample split (40 malignant, 30 benign), which should yield approximately 85.8%. The abstract claims 100% combined accuracy while the results report 97.3%.
  - Dimension: methodological rigour
  - Location: Abstract, Table 2, §3.6
- **Inappropriate biomarker selection for prostate cancer** AFP (alpha-fetoprotein) is described as a tumor marker for prostate cancer, but AFP is standard for hepatocellular carcinoma and germ cell tumors. PSA (prostate-specific antigen) is the established prostate cancer marker, raising fundamental questions about the biomarker panel's validity for this indication.
  - Dimension: methodological rigour
  - Location: §2.1, §3.4

## Reliability checks

Concerns (4 of 4 checks).

- **Internal coherence:** Concern. Multiple specific numerical and terminological inconsistencies undermine the reported diagnostic performance metrics. The TM accuracy figure (69.8%) is arithmetically inconsistent with the stated sensitivity, specificity, and sample split. The abstract claims 100% combined accuracy while the results report 97.3%. TSGF and TSGH are used interchangeably throughout the manuscript.
- **Research conduct:** Noted. Ethics approval and informed consent are declared but the institutional name is redacted as 'XXX Orthopedic Hospital,' making the ethics declaration unverifiable. No conflict of interest statement, protocol registration, or adherence to diagnostic accuracy reporting standards (e.g., STARD) is reported.
- **Reference integrity:** Clean. All 23 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Concern
- **Summary:** This paper was retracted on 2023-11-01. See notice: 10.1155/2023/9850875.
- **Last checked:** 2026-10-17
